Reference entry · Dual GIP/GLP-1 receptor agonist
Tirzepatide
Also known as: Dual GIP/GLP-1 agonist · Mounjaro/Zepbound (approved drug names)
- Class
- Dual GIP/GLP-1 receptor agonist
- Primary targets (literature)
- GIP receptor, GLP-1 receptor
- Regulatory context
- FDA-approved drug. RUO catalog material requires independent verification and is not a substitute for trial drug product.
Overview
Tirzepatide combines GIP and GLP-1 receptor agonism in a single acylated peptide — a distinct research object from GLP-1–selective molecules like semaglutide, with large published SURPASS and SURMOUNT trial programs.
Mechanism in research literature
Dual incretin receptor activation adds GIP-mediated pathways to GLP-1 biology, influencing insulin secretion, energy balance, and gastric motility in trial-defined populations.
Common research focus areas
- Dual incretin receptor pharmacology
- Phase 3 obesity and T2D endpoints
- Acylated peptide identity testing
- Comparison frameworks vs. single-target GLP-1 agonists
Full literature roundup
Read the cited research summary
A dual GIP/GLP-1 receptor agonist studied in metabolic research. Mechanism context, published evidence, and documentation expectations.
Tirzepatide research roundup · 5 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.